Thalidomide for treatment of multiple myeloma: 10 years later

Blood

Volumn 111, Issue 8, 2008, Pages 3968-3977

  Palumbo, Antonio ^a   Facon, Thierry ^b   Sonneveld, Pieter ^c   Bladè, Joan ^d   Offidani, Massimo ^e   Gay, Francesca ^a   Moreau, Philippe ^f   Waage, Anders ^g   Spencer, Andrew ^h   Ludwig, Heinz ⁱ   Boccadoro, Mario ^a   Harousseau, Jean Luc ^j  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIV LILLE   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h ALFRED HOSPITAL   (Australia)

ⁱ WILHELMINEN HOSPITAL   (Austria)

^j HÔTEL DIEU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTICOAGULANT AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; METHYLPREDNISOLONE; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; PAMIDRONIC ACID; PHENYTOIN; PREDNISOLONE; PREDNISONE; RESERPINE; SULFONAMIDE; THALIDOMIDE; VINCRISTINE; WARFARIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIRTH DEFECT; BLOOD TOXICITY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CATATONIA; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ENDOTHELIUM INJURY; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HEPATITIS; HUMAN; HYPERESTHESIA; HYPOTENSION; HYPOTHYROIDISM; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MACULOPAPULAR RASH; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RESPIRATION DEPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SINUS BRADYCARDIA; SKIN ATROPHY; SKIN TOXICITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; TREMOR; XEROSTOMIA; CHEMISTRY; DRUG CONTROL; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG AND NARCOTIC CONTROL; HUMANS; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 43249097561     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-117457     Document Type: Review

References (78)

1. Zwingenberger K, Wnendt S. Immunomodulation by thalidomide: systemic review of the literature and of unpublished observations. J Inflamm. 1996;46:177-211.
2. Hallek M, Leif Bergsagel P, Anderson KC. Multiple myeloma: increasing evidence for a multi- step transformation process. Blood. 1998;91:3-21.
3. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM- DR): role of integrins and resistance to apopto- sis in human myeloma cell lines. Blood. 1999; 93:1658-1667.
4. Bertolini F, Mingrone W, Alietti A, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis: analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol. 2001;12:987-990.
5. Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs. 2005;14:1411-1418.
6. Teo SK, Colburn WA, Tracewell WG, et al. Clinical pharmacokinetics of thalidomide. Clin Phar-macokinet. 2004;43:311-327.
7. Teo S, Sabourin P, O'Brien K, et al. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14:140-147.
8. Teo SK, Harden JL, Burke AB, et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos. 2001;29:1355-1357.
9. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
10. Barlogie B, Desikan R, Eddlemor P, et al. Ex-tented survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-494.
11. Cibeira MT, Rosinol L, Ramiro L, et al. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol. 2006;77:486-492.
12. Glasmacher A, Hahn A, Hoffmann F, et al. A systematic review of phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Hematol. 2005;132:584-593.
13. Rosinol L, Cibeira MT, Blade J, et al Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89:832-836.
14. Yakoub-Agha I, Doyen C, Hulin C, et al. Amulti-center prospective randomised study testing non inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study [abstract]. J Clin Oncol. 2006;24:7520.
15. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
16. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.
17. Palumbo A, Bertola A, Falco P, et al. Efficacy of low dose thalidomide as first salvage regimen in multiple myeloma. Hemat J. 2004;5:318-324.
18. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective therapy for advanced myeloma. Haematologica. 2001;86:399-403.
19. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination or refractory multiple myeloma. Ann Oncol. 2001;12:991-995.
20. Fermand JP, Jaccard A, Macro M, et al. A randomized comparison of dexamethasone + thalidomide (Dex/Tal) vs Dex + Placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM) [abstract]. Blood. 2006;108:Abstract 3563.
21. Offidani M, Corvatta L, Marconi M, et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J. 2004;5:312-317.
22. Palumbo A, Avonto I, Bruno B, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Hematol. 2006;76:273-277.
23. Srakovic G, Elson P, Trebisky B, et al. Use of melphalan, thalidomide and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol. 2002;19:219-226.
24. Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica. 2006;91:133-136.
25. Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsedrefractory multiple myeloma. Mayo Clin Proc. 2006;81:889-895.
26. Kyriakou C, Thomson K, D'Sa S, et al. Low dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Hematol. 2005;129:763-770.
27. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regiment for previously treated patients with multiple myeloma. Hematol J. 2004;5:112-117.
28. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18:856-863.
29. Kropff MH, Lang N, Bisping G, et al. Hyperfrac- tionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCTD) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003;122:607-616.
30. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775-779.
31. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436.
32. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39.
33. Macro M, Divine M, Uzunhan Y, et al. Dexamethasone+thalidomide (dex/thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial [abstract]. Blood. 2006;108:Abstract 57.
34. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexametha- sone for newly diagnosed myeloma. J Clin Oncol. 2002;20:3419-3423.
35. Ludwig H, Tothova E, Hajek R, et al. Thalidomide- dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: second interim analysis. Hematologica. 2007;1:Abstract 446.
36. Wang M, Weber D, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005;79:194-197.
37. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-831.
38. Facon T, Mary J, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-1218.
39. Hulin C, Facon T, Rodon P, et al. Melphalan-Prednisone-Thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients >75 years with multiple myeloma compared with Melphalan and Prednisone (MP) in a randomized, double blind, placebo-controlled trial IFM 01-01 [abstract]. Blood. 2007;110:Abstract 75.
40. Zervas K, Dimopoulus MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multi-center study. Ann Oncol. 2004;15:134-138.
41. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344:1951.
42. Schutt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol. 2005;74:40-46.
43. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1549-1551.
44. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006;108:2159-2164.
45. Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multi-center randomized trial of the Greek myeloma study group. Ann Oncol. 2007;18:1369-1375.
46. Minnema MC, Breitkreutz I, Auwerda Jja, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004;18:2044-2046.
47. Wu P, Davies FE, Horton C, et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma. 2006;47:2335-2338.
48. Sidra G, Williams CD, Russel NH, et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica. 2006;91:862-863.
49. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
50. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168-1171.
51. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004;126:715-721.
52. Rajkumar SV, Hussein M, Catalano J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma [abstract]. J Clin Oncol. 2006;24:7517.
53. Breitkreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 2007; 21:1294-1299.
54. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood. 2006;108:3289-3294.
55. Spencer A, Prince HM, Roberts A, et al. Thalidomide improve survivals when use after ASCT [abstract]. Hematologica. 2007;92:Abstract S7b.
56. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicentre randomized clinical trial. Blood. 2008;111:1805-1810.
57. Cavo M, Testoni N, Terragna C, et al. Up-front thalidomide-dexamethasone (thal) and double autologous transplantation (double TX) for multiple myeloma: comparison with double TX without added thalidomide and prognostic implications of chromosome 13 deletion and traslocation t(4;14) [abstract]. Blood. 2006;108:Abstract 3081.
58. Palumbo A, Bringhen S, Falco P, et al. Time to first progression, but not b2-microglobulin, predicts outcome in myeloma patients who received thalidomide as salvage therapy. Cancer. 2007;110:824-829.
59. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Safety. 1992;7:116-134.
60. Teo S, Morgan M, Stirling D, et al. Assessment of the in vitro and in vivo genotoxicity of thalomid (thalidomide). Teratog Carcinog Mutagen. 2000;20:301-311.
61. Smithells D. Does thalidomide cause second generation birth defects? Drug Safety. 1998;19:339-341.
62. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187-192.
63. Corso A, Lorenzi A, Terulla V, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004;83:588-591.
64. Kaushal V, Kaushal GP, Melkaveri SN, et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost. 2004;2:327- 334.
65. Streetly M, Hunt BJ, Parmar K, et al. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immuno-modulatory agent actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol. 2005;74:293-296.
66. Dimopoulos MA, Eleutherakis V. Adverse effects of thalidomide administration in patients with neoplastic disease. Am J Med. 2004;117:508-515.
67. Fahdi IE, Gaddam V, Saucedo JF, et al. Bradycardia during therapy for multiple myeloma with tha- lidomide. Am J Cardiol. 2004;93:1052-1055.
68. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507-4514.
69. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity and biological activity. Mayo Clin Proc. 2004;79:875-882.
70. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiology study. Neurology. 2004;62:2291.
71. Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002;119:1020-1026.
72. Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med. 2000;343:972-973.
73. Hall VC, El-Azhary RA, Bouwhuis S, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol. 2003;48:548-552.
74. Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002; 112:412-413.
75. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal cell carcinoma. Ann Oncol. 2002;13:1029-1035.
76. Trojan A, Chasse E, Gay B, et al. Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma. Ann Oncol. 2003;14:501-502.
77. Eriksson T, Hoglund P, Turesson I, et al. Pharma- cokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol. 2003;55:1701-1706.
78. Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73:98-103.